{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T18:14:13Z","timestamp":1778696053126,"version":"3.51.4"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004761","name":"the Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2025JJ50450"],"award-info":[{"award-number":["2025JJ50450"]}],"id":[{"id":"10.13039\/501100004761","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with severe asthma, particularly those with an eosinophilic phenotype, face a limited array of treatment options. The Mepolizumab Efficacy in Patients with Severe Asthma (MENSA) trial (clinicaltrials.gov NCT03562195) has underscored the potential therapeutic benefits of mepolizumab as an adjunctive treatment for this patient group. However, the high cost of mepolizumab therapy presents significant economic challenges that may impede its widespread adoption in China. This study aims to assess the cost-effectiveness of mepolizumab from a societal perspective within the Chinese population suffering from severe asthma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A Markov model spanning a lifetime horizon and employing a 2-week cycle was constructed. The model incorporated clinically significant exacerbations (CSEs) rates from the MENSA trial, along with asthma mortality rates, costs, and health state utilities, sourced from a broad spectrum of literature and national databases. Both costs and effectiveness outcomes were discounted annually at 5%. Incremental cost-effectiveness ratios (ICERs) were calculated as the primary model output and compared to a willingness-to-pay (WTP) threshold range of $15,217 to $38,042 per quality-adjusted life-years (QALY). The model\u2019s robustness was evaluated through sensitivity analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The base-case analysis indicated an ICER of $848.79 per QALY for mepolizumab, fall below the lower limit of the predefined WTP threshold. Subgroup analyses confirmed this finding across different subpopulations. Deterministic sensitivity analyses showed that mepolizumab\u2019s ICER remained below the lower limit of the predefined WTP threshold even under significant parameter variations. Probabilistic sensitivity analyses further demonstrated mepolizumab\u2019s cost-effectiveness advantage over placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study concluded that mepolizumab is a cost-effectiveness treatment option for severe asthma in China, applicable across various patient subgroups. This finding is crucial for healthcare decision-makers in China, where balancing cost and health outcomes is essential due to limited resources.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0348955","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:32:17Z","timestamp":1778693537000},"page":"e0348955","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness analysis of mepolizumab among patients with severe asthma from the Chinese societal perspective"],"prefix":"10.1371","volume":"21","author":[{"given":"Chaohao","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chongqing","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohui","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8739-6236","authenticated-orcid":true,"given":"Qiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"issue":"20","key":"pone.0348955.ref001","first-page":"1759","article-title":"Chinese expert consensus on the diagnosis and management of severe asthma (2024 edition)","volume":"104","author":"Chinese Education Association of Chronic Airway Diseases, China Asthma Alliance","year":"2024","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"pone.0348955.ref002","volume-title":"Global strategy for asthma management and prevention 2024","author":"Global Iniative for Asthma (GINA)","year":"2024"},{"issue":"10196","key":"pone.0348955.ref003","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(19)31147-X","article-title":"Prevalence, risk factors, and management of asthma in China: a national cross-sectional study","volume":"394","author":"K Huang","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"pone.0348955.ref004","first-page":"917","article-title":"A cross-section study of severe asthma in eight provinces of China","volume":"55","author":"N Su","year":"2016","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"12","key":"pone.0348955.ref005","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1016\/j.jaip.2023.07.041","article-title":"Severe asthma network Italy definition of clinical remission in severe asthma: a Delphi consensus","volume":"11","author":"GW Canonica","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"22","key":"pone.0348955.ref006","doi-asserted-by":"crossref","first-page":"14663","DOI":"10.3390\/ijerph192214663","article-title":"Prevalence and disability-adjusted life year rates of asthma in China: findings from the GBD study 2019 of the G20","volume":"19","author":"M Liu","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"3","key":"pone.0348955.ref007","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.chest.2021.04.013","article-title":"Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort","volume":"160","author":"LG Heaney","year":"2021","journal-title":"Chest"},{"issue":"1","key":"pone.0348955.ref008","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.alit.2022.11.008","article-title":"Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy","volume":"72","author":"H Nagase","year":"2023","journal-title":"Allergol Int"},{"issue":"4","key":"pone.0348955.ref009","first-page":"341","article-title":"Chinese expert consensus on the use of Omalizumab in allergic asthma (2021 version)","volume":"45","author":"Chinese Thoracic Society Asthma Group","year":"2022","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"issue":"3","key":"pone.0348955.ref010","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/all.15056","article-title":"From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases","volume":"77","author":"ID Pavord","year":"2022","journal-title":"Allergy"},{"key":"pone.0348955.ref011","volume-title":"Information on pending collection of drug approval documents issued on November 19, 2021","author":"National Medical Products Administration","year":"2021"},{"issue":"9842","key":"pone.0348955.ref012","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"ID Pavord","year":"2012","journal-title":"Lancet"},{"issue":"13","key":"pone.0348955.ref013","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"HG Ortega","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0348955.ref014","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"GL Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"3","key":"pone.0348955.ref015","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.alit.2016.11.006","article-title":"Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma","volume":"66","author":"T Shimoda","year":"2017","journal-title":"Allergol Int"},{"key":"pone.0348955.ref016","unstructured":"National Health Industry Data Platform: Drug Bid Winning. Available from: https:\/\/db.yaozh.com\/"},{"issue":"3","key":"pone.0348955.ref017","doi-asserted-by":"crossref","first-page":"00750","DOI":"10.1183\/23120541.00750-2023","article-title":"Efficacy and safety of mepolizumab in a Chinese population with severe asthma: a phase III, randomised, double-blind, placebo-controlled trial","volume":"10","author":"R Chen","year":"2024","journal-title":"ERJ Open Res"},{"issue":"1","key":"pone.0348955.ref018","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12962-024-00552-1","article-title":"An overview of the perspectives used in health economic evaluations","volume":"22","author":"M Sittimart","year":"2024","journal-title":"Cost Eff Resour Alloc"},{"key":"pone.0348955.ref019","unstructured":"World Bank. Out\u2011of\u2011pocket expenditure (% of current health expenditure). 2023. Available from: https:\/\/data.worldbank.org\/indicator\/SH.XPD.OOPC.CH.ZS?locations=CN"},{"key":"pone.0348955.ref020","volume-title":"China guidelines for pharmacoeconomic evaluations (2020 edition)","author":"Research Group of China Pharmacoeconomics Evaluation Guideline","year":"2020"},{"key":"pone.0348955.ref021","unstructured":"National Bureau of Statistics. Annual data. Available from: https:\/\/data.stats.gov.cn\/easyquery.htm?cn=C01"},{"issue":"1","key":"pone.0348955.ref022","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"25","author":"D Husereau","year":"2022","journal-title":"Value Health"},{"issue":"1","key":"pone.0348955.ref023","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1080\/13696998.2024.2385191","article-title":"Cost-effectiveness analysis of budesonide\/formoterol SMART therapy versus salmeterol\/fluticasone plus as-needed SABA among patients \u226512 years with moderate asthma from the Chinese societal perspective","volume":"27","author":"K Zhou","year":"2024","journal-title":"J Med Econ"},{"issue":"10","key":"pone.0348955.ref024","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1016\/j.jaip.2023.06.051","article-title":"Long-term cost-effectiveness of digital inhaler adherence technologies in difficult-to-treat asthma","volume":"11","author":"SJ van de Hei","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"pone.0348955.ref025","first-page":"1023","article-title":"Guidelines for prevention and treatment of bronchial asthma (2020 edition)","author":"Asthma Group, Respiratory Disease Branch CMA","year":"2020","journal-title":"Chin J Tuberc Respir Dis"},{"key":"pone.0348955.ref026","volume-title":"Study on the status and trends of asthma death burden in China","author":"Y C","year":"2023"},{"key":"pone.0348955.ref027","volume-title":"China population census yearbook","author":"Statistics NBo","year":"2020"},{"issue":"8","key":"pone.0348955.ref028","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-060160","article-title":"Real-life impact of uncontrolled severe asthma on mortality and healthcare use in adolescents and adults: findings from the retrospective, observational RESONANCE study in France","volume":"12","author":"N Roche","year":"2022","journal-title":"BMJ Open"},{"issue":"1","key":"pone.0348955.ref029","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2165\/00019053-200725010-00002","article-title":"Rates and probabilities in economic modelling: transformation, translation and appropriate application","volume":"25","author":"RL Fleurence","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"pone.0348955.ref030","unstructured":"Bid winning price of drugs: National Health Industry Data Platform. Available from: https:\/\/www.yaozh.com\/"},{"issue":"5","key":"pone.0348955.ref031","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/inthealth\/ihx030","article-title":"Charting a path forward: policy analysis of China\u2019s evolved DRG-based hospital payment system","volume":"9","author":"R Liu","year":"2017","journal-title":"Int Health"},{"issue":"7","key":"pone.0348955.ref032","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1080\/02770900500214783","article-title":"Length of stay and costs for asthma patients by hospital characteristics--a five-year population-based analysis","volume":"42","author":"H-C Lin","year":"2005","journal-title":"J Asthma"},{"issue":"1","key":"pone.0348955.ref033","article-title":"Economic burden of asthma in Singapore","volume":"8","author":"EA Finkelstein","year":"2021","journal-title":"BMJ Open Respir Res"},{"key":"pone.0348955.ref034","doi-asserted-by":"crossref","first-page":"908837","DOI":"10.3389\/fphar.2022.908837","article-title":"Health-related quality of life in adult patients with asthma according to asthma control and severity: A systematic review and meta-analysis","volume":"13","author":"B-C Oh","year":"2022","journal-title":"Front Pharmacol"},{"key":"pone.0348955.ref035","first-page":"1","article-title":"Treatment options for advanced non-small cell lung cancer: effectiveness, value and value-based price benchmarks","volume-title":"Final evidence report and meeting summary","year":"2016"},{"issue":"4","key":"pone.0348955.ref036","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s10198-021-01384-z","article-title":"Estimation of the cost-effective threshold of a quality-adjusted life year in China based on the value of statistical life","volume":"23","author":"D Cai","year":"2022","journal-title":"Eur J Health Econ"},{"key":"pone.0348955.ref037","doi-asserted-by":"crossref","first-page":"1408928","DOI":"10.3389\/fimmu.2024.1408928","article-title":"First-line treatments for extensive-stage small-cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a China-based cost-effectiveness analysis","volume":"15","author":"L Yi","year":"2024","journal-title":"Front Immunol"},{"issue":"8","key":"pone.0348955.ref038","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.71244","article-title":"Cost-utility of fluticasone propionate\/salmeterol and fluticasone propionate monotherapy in step-up treatment of childhood asthma","volume":"60","author":"JA Buend\u00eda","year":"2025","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"pone.0348955.ref039","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1080\/13696998.2025.2520701","article-title":"Cost-effectiveness of mepolizumab vs anti-interleukin-5\/5r biologic therapies for the treatment of adults with severe asthma with an eosinophilic phenotype: a Chilean healthcare system perspective","volume":"28","author":"F Moraes Dos Santos","year":"2025","journal-title":"J Med Econ"},{"issue":"5","key":"pone.0348955.ref040","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1177\/0272989X12458348","article-title":"Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6","volume":"32","author":"AH Briggs","year":"2012","journal-title":"Med Decis Making"},{"issue":"9","key":"pone.0348955.ref041","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1080\/02770903.2024.2324855","article-title":"Cost-effectiveness of mepolizumab for severe eosinophilic asthma in China","volume":"61","author":"X Chaogang","year":"2024","journal-title":"J Asthma"},{"key":"pone.0348955.ref042","doi-asserted-by":"crossref","first-page":"106483","DOI":"10.1016\/j.rmed.2021.106483","article-title":"Developing a short-term prediction model for asthma exacerbations from Swedish primary care patients\u2019 data using machine learning - Based on the ARCTIC study","volume":"185","author":"K Lisspers","year":"2021","journal-title":"Respir Med"},{"issue":"1","key":"pone.0348955.ref043","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s40273-020-00986-4","article-title":"Use of productivity loss\/gain in cost-effectiveness analyses for drugs: a systematic review","volume":"39","author":"A Yuasa","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"pone.0348955.ref044","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s40273-024-01402-x","article-title":"A systematic review of methods for estimating productivity losses due to illness or caregiving in low- and middle-income countries","volume":"42","author":"E Setiawan","year":"2024","journal-title":"Pharmacoeconomics"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0348955","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:32:28Z","timestamp":1778693548000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0348955"}},"subtitle":[],"editor":[{"given":"Guillermo","family":"Salinas-Escudero","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":44,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0348955","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]}}}